PREVENA™ Incision Management System is a negative pressure wound therapy device intended for use on surgical incisions that continue to drain following sutured or stapled closures.
• Holds incision edges together
• Protects incision site from external infectious sources
• Removes fluids and infectious materials from the surgical site
• Lightweight and portable
• Available in three Peel & Place™ versions (13cm, 20cm and 35cm) for linear incisions
• Available in a Customizable™ version for linear and non-linear incisions up to 90cm
• Available in DUO™ version with three different configurations (13cm/13cm, 13cm/20cm and 20cm/20cm) which can manage two incisions at the same time
• Dressing may be connected directly to a V.A.C.® Therapy Unit
PREVENA™ 125 and PREVENA PLUS™ 125 Therapy Units manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125mmHg continuous negative pressure. When used with legally marketed compatible dressings, PREVENA™ 125 and PREVENA PLUS™ 125 Therapy Units are intended to aid in reducing the incidence of seroma in patients at high risk for post-operative infections and aid in reducing the incidence of superficial surgical site infection in Class I and Class II wounds.
Contraindicated for patients with a sensitivity to silver.
Before applying the PREVENA™ Incision Management System to patients who are at risk of bleeding complications due to the operative procedure or concomitant therapies and/or co-morbidities, ensure that homeostasis has been achieved and all tissue planes have been approximated. If active bleeding develops suddenly or in large amounts during therapy, or if frank blood is seen in the tubing or canister, the patient should leave the Incision dressing in place, turn off Therapy Unit and seek immediate emergency medical assistance. As with any wound treatment, clinicians and patients/caregivers should frequently monitor the patient's wound, periwound tissue and exudate for signs of infection, or other complications. Some signs of infection are fever, tenderness, redness, swelling, itching, rash, increased warmth in the wound or periwound area, purulent discharge, or strong odor. Infection can be serious, and can lead to complications such as pain, discomfort, fever, gangrene, toxic shock, septic shock and/or fatal injury. Some signs or complications of systemic infection are nausea, vomiting, diarrhea, headache, dizziness, fainting, sore throat with swelling of the mucus membranes, disorientation, high fever, refractory and/or orthostatic hypotension, or erythroderma (a sunburn-like rash). Silver in the interface layer of the Incision Dressing is not intended to treat infection, but to reduce bacterial colonization in the fabric. If infection develops, therapy should be discontinued until the infection is treated. Remove the Incision Dressing if defibrillation is required in the area of the dressing placement. Failure to remove the dressing may inhibit transmission of electrical energy and/or patient resuscitation. The PREVENA™ Incision Management System is MR Unsafe. Do not take the Therapy Unit into the MR environment. The Incision Dressing can typically remain on the patient with minimal risk in an MR environment. Interruption of Therapy during an MRI may reduce the effectiveness of therapy. The Incision Dressing should pose no known hazards in an MR environment with the following conditions of use: static magnetic field of 3 Tesla or less, spatial gradient field of 720 Gauss/cm or less, and maximum whole-body-averaged specific absorption rate (SAR) of 3W/kg for 15 minutes of scanning. The Incision Dressing contains metallic silver that may impair visualization with certain imaging modalities. Do not take the PREVENA™ Incision Management System or Incision Dressing into a hyperbaric oxygen chamber; it is not designed for this environment and should be considered a fire hazard. If therapy is reinitiated after HBO treatment, do not readhere the same dressing; a new dressing must be reapplied. If at any time while using the PREVENA™ Incision Management System, the canister becomes full of fluid other than blood, indicated by a Maximum Capacity Alert or visual inspection, the patient should turn therapy unit off and contact the treating physician.
Allergic Response: The Incision Dressing has an acrylic adhesive coating and a skin interface layer with silver, which may present a risk of an adverse reaction in patients who are allergic or hypersensitive to acrylic adhesives or silver. If a patient has a known allergy or hypersensitivity to these materials, do not use the PREVENA™ Incision Management System. If any signs of allergic reaction, irritation or hypersensitivity develop, such as redness, swelling, rash, urticaria, or significant pruritus, patient should consult a physician immediately. If bronchospasm or more serious signs of allergic reaction appear, the patient should turn off the therapy unit and seek immediate emergency medical assistance.
Do not expose to high temperature (60°C/140°F).
|Accommodates large wounds|
|Accommodates small wounds|
|Antimicrobial interface available||●|
|Portable (under 1lb)||●|
|Single-use – 10 days|
|Single-use – 15 days|
|Single-use – 30 days|
|Single-use – 7 days||●|
|Usable on closed wounds||●|
|Usable on open wounds|
|Variable pressure setting|
|Educational Material Available||●|
|Free Samples/Trials Available||●|
|Published Clinical Article Available||●|
For maximum benefit the PREVENA™ Incision Management System should be applied immediately post surgery to clean surgically closed wounds. It is to be continuously applied for a minimum of two days up to a maximum of seven days. It can transition home with the patient; however, all Incision Dressing changes should be performed under direct medical supervision.
Open the sterile dressing package and remove dressing and patch strips using aseptic technique. DO NOT use if package has been torn or the sterile seal has been compromised. Gently peel back the center strip on the back of the dressing, exposing the pull tabs and adhesive. Center and apply the dressing over the closed wound or incision ensuring that the adhesive will not contact or cover the surgical closure. Orient the dressing on the patient to eliminate sharp bends/kinks in the tubing. Remove the remaining bottom adhesive covers by grasping the bottom tabs and gently pulling. Firmly press around the dressing to ensure a good seal where the adhesive contacts the skin. Remove top stabilization layers. Remove the 45ml Canister from the sterile package. DO NOT use if package has been torn or the sterile seal has been compromised. Connect the dressing tubing to the canister tubing by twisting the connectors until they lock. Insert the canister into the PREVENA™ Incision Management System Therapy Unit, and slide inward until canister clicks. Canister is fully inserted when the side tabs are flush with the body of the therapy unit. Therapy can now begin. To begin therapy, press and hold the ON/OFF button for two seconds; an audible beep will confirm that the therapy is on. A green LED on the front of the unit indicates that therapy is on. With therapy on, assess dressing to ensure integrity of seal. The dressing should have a wrinkled appearance and the foam bolster should be compressed. The Pressure Indicator on the dressing should be in the collapsed position. Place the therapy unit into the Carrying Case. Make sure that the display is visible through the opening in the Carrying Case when the front flap is lifted.
Indicated for up to seven days of use. No dressing changes needed.
PREVENA PLUS™ 125 Therapy Unit
Negative Pressure Options: Pre-set, continuous NPWT at -125mmHg
Weight with empty canister: 0.7lb (0.32kg)
Dimensions: Approximately 16cmx9cmx3cm
PREVENA PLUS™ 150ml Canister
150ml canister with connecting tubing
Single use, sterile, disposable
Canister dimensions: 15.5cmx9cmx2.5cm
PREVENA PLUS™ Connector Tube length: 45cm
Acelity leverages the strengths of Kinetic Concepts and Systagenix Wound Management to provide a trusted and complementary portfolio of advanced wound therapeutics for customers and patients in more than 90 countries worldwide.